Stocks and Investing
Stocks and Investing
Mon, August 21, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Yigal Nochomovitz Maintained (ATRA) at Strong Sell with Decreased Target to $35 on, Aug 21st, 2023
Yigal Nochomovitz of Citigroup, Maintained "Atara Biotherapeutics, Inc." (ATRA) at Strong Sell with Decreased Target from $50 to $35 on, Aug 21st, 2023.
Yigal has made no other calls on ATRA in the last 4 months.
There are 3 other peers that have a rating on ATRA. Out of the 3 peers that are also analyzing ATRA, 0 agree with Yigal's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Yigal
- Anthony Butler of "EF Hutton" Reiterated at Strong Buy and Held Target at $625 on, Wednesday, August 9th, 2023
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $700 on, Wednesday, June 14th, 2023
- John Newman of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $500 on, Tuesday, May 9th, 2023
Contributing Sources